Veltuzumab

Veltuzumab is a monoclonal antibody (targeted at CD20) which is being investigated for the treatment of non-Hodgkin's lymphoma.^[1][2] As of December 2011^[update], it is undergoing Phase I/II clinical trials.^[3] When used with milatuzumab it showed activity.^[4]

Veltuzumab

Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	CD20
Clinical data
ATC code	none
Identifiers
CAS Number	728917-18-8 N
ChemSpider	none
UNII	BPD4DGQ314
Chemical and physical data
Formula	C6458H9918N1706O2026S46
Molar mass	145349.06 g·mol−1
NY (what is this?)  (verify)

This drug was developed by Immunomedics, Inc. and was originally known as IMMU-106.^[5]

In August 2015 the US FDA granted it orphan drug status for immune thrombocytopenia (ITP).^[6] A phase II trial is planned to run for 5 years.^[6]

See also

• CD20 antagonist